

**NEUTRISCI INTERNATIONAL INC.  
MANAGEMENT'S DISCUSSION AND ANALYSIS  
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017**

---

**Date: November 29, 2017**

**MANAGEMENT'S RESPONSIBILITY FOR FINANCIAL REPORTING**

This management's discussion and analysis ("MD&A") reports on the operating results and financial condition of NeutriSci International Inc. ("NeutriSci" or the "Company") for the nine months ended September 30, 2017 and is prepared as at November 29, 2017. This MD&A should be read in conjunction with the Company's unaudited condensed consolidated interim financial statements for the nine months ended September 30, 2017 and audited financial statements for the year ended December 31, 2016 and the notes thereto which were prepared in accordance with International Financial Reporting Standards ("IFRS") (the "Financial Statements"). Other information contained in these documents has also been prepared by management and is consistent with the data contained in the Financial Statements. All dollar amounts referred to in this MD&A are expressed in Canadian dollars except where indicated otherwise.

The Company's certifying officers, based on their knowledge, having exercised reasonable diligence, are also responsible to ensure that these filings do not contain any untrue statements of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by these filings, and these financial statements together with the other financial information included in these filings fairly present in all material respects the financial condition, results of operations and cash flows of the Company, as of the date of and for the periods presented in this MD&A. The Board of Directors' approves the Financial Statements and MD&A and ensures that management has discharged its financial responsibilities. The Board's review is accomplished principally through the Audit Committee, which meets periodically to review all financial reports, prior to filing.

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION**

This MD&A includes "forward-looking statements", within the meaning of applicable securities legislation, which are based on the opinions and estimates of Management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions, or other future performance suggested herein.

Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "budget", "plan", "continue", "estimate", "expect", "forecast", "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe" and similar words suggesting future outcomes or statements regarding an outlook. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. These forward looking statements include but are not limited to statements concerning:

- The Company's outstanding indebtedness, and the Company's intentions with respect to the repayment or refinancing of that indebtedness
- The Company's success at completing future financings
- The Company's sales and marketing strategies and objectives

# **NEUTRISCI INTERNATIONAL INC.**

## **MANAGEMENT'S DISCUSSION AND ANALYSIS**

### **FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017**

---

- The Company's cost reductions and other financial operating objectives
- The availability of qualified employees for business operations
- General business and economic conditions
- The Company's ability to meet its financial obligations as they become due
- The positive cash flows and financial viability of its new product lines
- The Company's ability to manage growth with respect to its business
- The Company's tax position, anticipated tax refunds and the tax rates applicable to the Company

Readers are cautioned that the preceding list of risks, uncertainties, assumptions and other factors are not exhaustive. Events or circumstances could cause actual results to differ materially from those estimated or projected and expressed in, or implied by these forward looking statements. Due to the risks, uncertainties and assumptions inherent in forward-looking statements, investors in securities of the Company should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this document are made as of the date hereof.

## **OVERVIEW**

NeutriSci International Inc. (the "Company" or "NeutriSci") was incorporated under the laws of the Province of Alberta on September 9, 2009 and was continued into British Columbia under the BCBCA on November 26, 2014 in conjunction with the reverse take-over of Disani Capital Corp. The Company's shares are listed on Tier 2 of the TSX Venture Exchange (the "Exchange") under the symbol "NU". The Company's head office is at 4015 - 1st Street SE, Calgary, Alberta T2G 4X7 and the Company's registered office is 2200 – 885 West Georgia Street, Vancouver BC, Canada, V6C 3E8.

NeutriSci is focused on the market development for its nutraceutical products.

NeutriSci's products utilize a unique and patented form of Pterostilbene called pTeroPure®. pTeroPure® Pterostilbene is a form of all-trans Pterostilbene that is found naturally in blueberries, and is manufactured for NeutriSci by ChromaDex Corp. ("ChromaDex") in the US. NeutriSci has recently launched neuenergy®, a new and innovative energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. The efficacy of neuenergy® is based on a molecular combination of pTeroPure® Pterostilbene and a low dose of caffeine, called PurEnergy® (also manufactured by ChromaDex). The resulting co-crystal provides a novel, next-generation alternative to high-dose caffeine products and is the base ingredient of neuenergy®. In clinical studies, the co-crystal ingredient demonstrated a significantly more efficient cellular uptake when compared with standard caffeine alone. neuenergy® offers consumers a great-tasting, safe and very effective alternative to today's high-caffeine energy products.

The Company has a history of losses and anticipates further losses in the development of its business. As at September 30, 2017, the Company has an accumulated deficit of \$27,741,399 (December 31, 2016 - \$26,057,382). Continuing business as a going concern is dependent upon the success of the neuenergy® product in the retail storefront and online markets, the existing cash flows, and the ability of the Company to obtain additional debt or equity financing all of which are uncertain. These material uncertainties may cast significant doubt on the Company's ability to continue as a going concern.

# NEUTRISCI INTERNATIONAL INC.

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017

---

#### DEVELOPMENTS

The Company has been focusing its efforts on developing and growing the market for neuenergy®. The Company's primary focus is on establishing and setting up distribution within Chain and Drug/Mass retailers such as Meijer; Convenience stores such as 7-Eleven, Mac's, Gateway and Winks; Grocery – Buy-Low and Save-On-Foods; as well as online distribution such as Amazon, and through the Company's own product website.

Key and strategic milestones met during the period include:

- Secured a distribution agreement with Sobeys Inc. and Safeway Canada both of which are wholly owned subsidiaries of Empire Co. Ltd. Empire is one of the largest food retailers in Canada, with over 260 Sobeys and 183 Safeway supermarkets operating in Canada.
- Signed a distribution agreement with Gateway Newstands. neuenergy® is now available at Gateway Newstands across Canada and the United States.
- NeutriSci's common shares are now dual-listed on the TSX Venture Exchange and the Frankfurt Stock Exchange, one of the largest stock exchanges in the world. Additionally, the Company successfully commenced trading on the OTCQB Marketplace under the symbol NRXCF.
- Completed redesign of external packaging for neuenergy® based on distributor and consumer feedback. External packaging has been significantly reduced to make the product easier for retailers to display at check-outs. This redesign has resulted in a 24% reduction in packaging and manufacturing costs.
- Entered into a 50/50 Joint Venture with Lexaria Bioscience Corp. ("Lexaria") to develop and produce a line of healthy edible cannabinoid products using Lexaria's patented technology and NeutriSci's proprietary Pterostilbene tablet formula and to distribute the products through NeutriSci's international distribution network.
- The Company received the successful approval and registration of certain trademarks, specifically – neuenergy®, Powered by Blueberries, neuenergy® design, the neuenergy® logo and an Industrial Design Registration for the neuenergy® orange stick.

#### OUTLOOK

As the Company moves through 2017; it will continue its expansion of the neuenergy® distribution network in Canada, the USA and International markets. The Company is focused on driving sales and growing product awareness through its expanded marketing and branding initiatives; programs that have already started to demonstrate success. In addition to the mass media marketing programs the Company has already begun, NeutriSci has committed to launch an online ambassador program as well as an aggressive instore marketing strategy with key retailers both in Canada and the US to compliment the overall strategy.

The popularity of neuenergy® has started to become evident by the amount of third party groups inquiring about their desire to obtain international distribution rights for neuenergy®. These inquiries align directly with the Company's long-term strategic plan to market neuenergy® to a global audience thus increasing shareholder value and global brand awareness. The Company is currently working towards establishing distribution and licensing agreements in Southeast Asia, India and China.

In January 2017, NeutriSci and Lexaria successfully developed and completed the initial trial of the industry's first cannabinoid (CBD)/pterostilbene edible tablet, utilizing NeutriSci's and Lexaria's proprietary and patented technologies. NeutriSci's proprietary Pterostilbene tablet formula and Lexaria's technology were combined to

**NEUTRISCI INTERNATIONAL INC.**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017**

---

produce the first market-ready Pterostilbene/cannabidiol rapid-melt edible product. The pretrial hypothesis focused on whether the combination of NeutriSci's patented Pterostilbene formula and Lexaria's patented CBD conjugation would prove effective in rapidity of onset, and strength of effect, while delivering improvements in taste. Initial trial results demonstrated that the consumer experiences positive effects that occur more immediately, and last longer, while utilizing dose-controlled amounts of CBD. Based on these positive results, NeutriSci and Lexaria have formalized the JV agreement to market and commercialize a line of edible products using CBD derived from full-spectrum hemp oil, which is legal throughout the United States, along with several tetrahydrocannabinol versions, through distribution programs with both existing and new strategic partners. The new company, Ambarii Trade Corporation, is owned 50/50 with Lexaria.

**SUMMARY OF QUARTERLY RESULTS<sup>1</sup>**

	<b>3<sup>rd</sup> Quarter Ended Sept 30, 2017</b>	<b>2<sup>nd</sup> Quarter Ended Jun 30, 2017</b>	<b>1<sup>st</sup> Quarter Ended Mar 31, 2017</b>	<b>4<sup>th</sup> Quarter Ended Dec 31, 2016</b>
Total revenue	\$39,837	\$27,983	\$34,433	\$32,154
Net loss and comprehensive loss	\$(471,679)	\$(523,672)	\$(688,541)	\$(816,960)
Basic and diluted loss per share	\$(0.01)	\$(0.01)	\$(0.01)	\$(0.01)

	<b>3<sup>rd</sup> Quarter Ended Sept 30, 2016</b>	<b>2<sup>nd</sup> Quarter Ended Jun 30, 2016</b>	<b>1<sup>st</sup> Quarter Ended Mar 31, 2016</b>	<b>4<sup>th</sup> Quarter Ended Dec 31, 2015</b>
Total revenue	\$40,392	\$34,944	\$17,861	\$(2,617)
Net loss and comprehensive loss	\$(600,910)	\$(439,127)	\$(707,833)	\$(2,347,882)
Basic and diluted loss per share	\$(0.01)	\$(0.01)	\$(0.01)	\$(0.05)

*1 Financial information prepared using accounting policies consistent with IFRS as issued by the International Accounting Standard Board ("IASB") and in accordance with International Accounting Standards ("IAS") 34, Interim Financial Reporting*

The Company is focusing its efforts on developing and growing the market for its newest product, neuenergy®. The Company's primary focus during the fourth quarter of 2015 was on setting up retail distributors. The results during 2015 reflect minimal sales through distributors established during the year. During 2016, the retail distributors established in 2015 started to load in product into their retail chains. The Company's sales increased through the fourth quarter of 2016. Sales have maintained stability in 2017.

During the three months ended December 31, 2015, on the basis that the Company was not actively marketing its BluScience™ product line, the Company recorded an impairment write-down for the BluScience™ product inventory of \$1,614,388.

**NEUTRISCI INTERNATIONAL INC.  
MANAGEMENT'S DISCUSSION AND ANALYSIS  
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017**

---

**RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2017**

The following is an analysis of the Company's operating results for the three months ended September 30, 2017, and includes a comparison against the three months ended September 30, 2016.

**Sales revenue**, which consisted primarily of sales of the neuenergy® product line for the three months ended September 30, 2017 was \$39,837, as compared to \$40,392 for the three months ended September 30, 2016. The Company continues to work with its distribution partners to grow the sales of its neuenergy® product.

**Cost of sales** for the three months ended September 30, 2017 was \$34,802, as compared to \$33,250 for the three months ended September 30, 2016. Costs during the period were slightly higher due to costs associated with repackaging of the neuenergy® product.

**Operating expenses** for the three months ended September 30, 2017 were \$381,559, as compared to \$303,208 for the three months ended September 30, 2016. This increase in operating expenses during the period was mainly due to higher advertising and promotion. This increase is partially offset by a decrease in travel expenses.

**General and administrative costs** for the three months ended September 30, 2017 were \$89,691 as compared to \$270,261 for the three months ended September 30, 2016. The decrease in general and administrative expenses is the result of a decrease in professional fees during the period. Professional fees in 2016 were higher due to monies spent with professionals to develop a plan to increase the neuenergy® awareness.

**Finance expenses** for the three months ended September 30, 2017 were \$1,750 as compared to \$32,308 for the three months ended September 30, 2016. The decrease is due to a reduction in interest on a declining note payable balance outstanding, as significant principal payments have been made during the period.

**Comprehensive loss for the period**

As a result of the activities discussed above, the Company experienced a comprehensive loss for the three months ended September 30, 2017 of \$471,679 as compared to comprehensive loss of \$600,910 for the three months ended September 30, 2016.

**RESULTS OF OPERATIONS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017**

The following is an analysis of the Company's operating results for the nine months ended September 30, 2017, and includes a comparison against the nine months ended September 30, 2016.

**Sales revenue**, which consisted primarily of sales of the neuenergy® product line for the nine months ended September 30, 2017 was \$102,253, as compared to \$93,198 for the nine months ended September 30, 2016. The slight increase is due to an increase in distribution partners.

**Cost of sales** for the nine months ended September 30, 2017 was \$100,749, as compared to \$71,184 for the nine months ended September 30, 2016. Costs during the current period were higher due to costs associated with repackaging of the neuenergy® product and the Company incurring approximately \$15,000 in one-time costs, which are not expected to recur going forward.

# NEUTRISCI INTERNATIONAL INC.

## MANAGEMENT'S DISCUSSION AND ANALYSIS

### FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017

---

**Operating expenses** for the nine months ended September 30, 2017 were \$1,260,234, as compared to \$1,235,624 for the nine months ended September 30, 2016. This slight increase in operating expenses is due to additional salaries and share based payments, which was partially offset by a reduction in consulting fees, as the Company ramps up its operations in connection with expanding distribution of neuenergy®.

**General and administrative costs** for the nine months ended September 30, 2017 were \$395,889 as compared to \$571,807 for the nine months ended September 30, 2016. The decrease in general and administrative expenses is the result of a decrease in professional fees during the period. Professional fees in 2016 were higher due to monies spent with professionals to develop a plan to increase the neuenergy® awareness.

**Finance expenses** for the nine months ended September 30, 2017 were \$28,196 as compared to \$41,433 for the nine months ended September 30, 2016. The decrease is due to a reduction in interest on a declining note payable balance outstanding, as significant principal payments have been made during the period.

#### **Comprehensive loss for the period**

As a result of the activities discussed above, the Company experienced a comprehensive loss for the nine months ended September 30, 2017 of \$1,683,892 as compared to comprehensive loss of \$1,747,871 for the nine months ended September 30, 2016.

## **RISKS AND UNCERTAINTIES**

The significant risks and uncertainties of the Company are detailed in management's discussion and analysis for the year ended December 31, 2016. There have been no material changes in the period.

## **LIQUIDITY AND CAPITAL RESOURCES**

The Company defines capital as consisting of shareholder's equity. The Company's objectives when managing capital are to support the identification and acquisition of a new business opportunity, and thus the creation of shareholder value, as well as to ensure that the Company is able to meet its financial obligations as they become due.

The Company manages its capital structure to maximize its financial flexibility making adjustments to it in response to changes in economic conditions and the risk characteristics of the underlying assets and business opportunities. The Company does not presently utilize any quantitative measures to monitor its capital, but rather relies on the expertise of the Company's management to sustain the future development of the business. Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. As at September 30, 2017, the Company is not subject to any externally imposed capital requirements or debt covenants. There was no change to the Company's approach to capital management during the nine months ended September 30, 2017.

The Company's objective in managing liquidity risk is to maintain sufficient liquidity in order to meet operational and investing requirements at any point in time. The Company has historically financed its operations primarily through debt and the sale of share capital by way of private placements.

The Company has a history of losses. The future success of the Company is dependent on the success of its nutraceutical products in the market together with the ability to finance the necessary funding, at agreeable

**NEUTRISCI INTERNATIONAL INC.**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017**

---

terms, to support the growth of the business. As at September 30, 2017, the Company had an accumulated deficit of \$27,741,274 (December 31, 2016 - \$26,057,382) and current assets of \$351,560, including a cash balance of \$32,007, to settle current liabilities of \$591,323.

The Company had an opening cash position of \$805,789. During the nine months ended September 30, 2017, operating activities consumed cash of \$1,152,960. During the period, the Company repaid US\$155,904 (Cdn\$206,786) on the US\$500,000 note payable of which US\$38,192 remains outstanding. The Company raised \$371,964 through a private placement and \$125,000 pursuant to the exercise of warrants. As a result of these activities, the Company experienced a net decrease in cash for the nine months ended September 30, 2017 of \$773,782; leaving the Company with a September 30, 2017 cash balance of \$32,007.

The Company expects to incur further losses in the development of its business over the next twelve months and will require additional cash to support these operations. As such the Company is subject to significant liquidity risk.

Consequently, the Company will require additional financing to accomplish its long term strategic objectives. Future funding may be obtained by means of issuing share capital, the exercise of the Company's stock options, the exercise of warrants, the exercise of broker warrants, and/or debt financing.

There can be no certainty of the Company's ability to raise additional financing through these means. If the Company is unable to finance itself through these means, it is possible that the Company will be unable to continue as a going concern. These factors raise significant doubt as to the ability of the Company to continue as a going concern.

The Company's condensed consolidated interim financial statements have been prepared in accordance with IFRS under the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business rather than a process of forced liquidation. These condensed consolidated interim financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.



**NEUTRISCI INTERNATIONAL INC.  
MANAGEMENT'S DISCUSSION AND ANALYSIS  
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017**

**(d) Warrants**

The following summarizes the warrant activity:

	Number of Warrants	Weighted average exercise price
<b>Total warrants outstanding, December 31, 2016</b>	<b>33,733,533</b>	<b>\$ 0.21</b>
Expired	(3,942,333)	0.21
Issued	3,333,000	0.12
Exercised	(1,250,000)	0.10
<b>Balance, September 30, 2017</b>	<b>31,874,200</b>	<b>\$ 0.21</b>
Expired	(11,874,200)	0.25
Issued	4,636,429	0.18
<b>Total warrants outstanding at the date of this MD&amp;A</b>	<b>24,636,429</b>	<b>\$ 0.18</b>

A summary of warrants outstanding at the date of this MD&A are as follows:

Number of Warrants outstanding	Weighted Average Exercise Price	Expiry date
1,667,000	\$0.25	September 30, 2021
15,000,000	\$0.18	May 7, 2018
3,333,000	\$0.20	November 2, 2018
4,636,429	\$0.12	October 6, 2018
24,636,429	\$0.18	

**(e) Finders' Warrants**

A summary of the Company's finders' warrants activity is as follows:

	Number of Options	Weighted Average Exercise Price
<b>Total finder's warrants outstanding, December 31, 2016</b>	<b>1,442,640</b>	<b>\$ 0.38</b>
Issued	233,310	0.20
<b>Total finder's warrants outstanding, September 30, 2017</b>	<b>1,675,950</b>	<b>\$ 0.18</b>
Issued	213,500	0.12
Expired	(596,640)	0.18
<b>Total finder's warrants outstanding at the date of this MD&amp;A</b>	<b>1,292,810</b>	<b>\$ 0.18</b>

A summary of finders' warrants outstanding at the date of this MD&A are as follows:

Number of Warrants outstanding	Weighted Average Exercise Prices	Expiry date
846,000	\$0.18	May 18, 2018
233,310	\$0.20	November 2, 2018
213,500	\$0.12	October 6, 2018

**NEUTRISCI INTERNATIONAL INC.  
MANAGEMENT'S DISCUSSION AND ANALYSIS  
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017**

**RELATED PARTY TRANSACTIONS**

The Company had transactions with the following related parties:

<b>Related party</b>	<b>Relationship</b>
Anfield Sujir Kennedy Durno LLP ("ASKD LLP")	Director of the Company was formerly a partner at the law firm
Cassels Brock & Blackwell LLP	Director of the Company is a partner at the law firm
Emprise Capital Corp.	Directors and Officers in common with the Company
Lexaria Bioscience Corp.	Joint Venture partner
Ambarii Trade Corporation	Investment in associate

The Company incurred the following expenses with companies controlled by directors and officers of the Company.

<b>Name of the related party</b>	<b>Nature of the Services</b>	<b>September 30, 2017</b>	<b>September 30, 2016</b>
Cassels Brock & Blackwell LLP	Legal	\$ 13,432	\$ 34,499
Emprise Capital Corp.	Management	135,000	151,000
		<b>\$ 148,432</b>	<b>\$ 185,499</b>

The following table comprises amounts due to related parties included within accounts payable and accrued liabilities:

	<b>September 30, 2017</b>	<b>December 31, 2016</b>
Directors of the Company	\$ 2,500	\$ 2,500
ASKD LLP	28,984	28,982
Cassels Brock & Blackwell LLP	15,167	-
<b>Total</b>	<b>\$ 46,651</b>	<b>\$ 31,482</b>

The following table comprises amounts due from related parties for expense advances:

	<b>September 30, 2017</b>	<b>December 31, 2016</b>
Officer/Director	\$ 55,427	\$ 33,458
Director	13,528	13,528
Related entity	4,758	-
	<b>\$ 73,713</b>	<b>\$ 46,986</b>

**NEUTRISCI INTERNATIONAL INC.**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017**

---

**Key management personnel compensation:**

Key management personnel include those persons having the authority and responsibility for planning, directing and controlling the activities of the Company. The Company has determined that key management personnel consists of the Company's executive and non-executive directors, officers and senior management.

	<b>September 30, 2017</b>	<b>September 30, 2016</b>
Salaries and benefits	<b>\$ 120,735</b>	\$ 120,881
Management fees paid to directors	<b>7,500</b>	7,500
Share-based payments	<b>30,995</b>	52,306
	<b>\$ 159,230</b>	\$ 180,687

**FINANCIAL INSTRUMENTS**

(a) Fair Value

The fair values of cash, receivables, due from related parties, goods and services tax receivable, accounts payable and accrued liabilities, and notes payable approximate their carrying values due to their short term maturity.

(b) Financial Risk Factors

The Company's risk exposure and the impact on the Company's financial instruments are summarized below:

I. Currency risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. As at September 30, 2017 the Company has a note payable due in the amount of US\$95,904 (Note 9 of the accompanying unaudited condensed consolidated interim financial statements). The balance is subject to foreign exchange fluctuation.

II. Interest rate risk

Interest risk is the risk that the fair value of future cash flows will fluctuate as a result of changes in interest rates. The Company's sensitivity to interest rates is currently immaterial.

III. Price risk

The Company is exposed to price risk with respect to equity prices. Equity price risk is defined as the potential adverse impact on the Company's earnings due to movements in individual equity prices or general movements in the level of the stock market. The Company closely monitors individual equity movements, and the stock market to determine the appropriate course of action to be taken by the Company.

**NEUTRISCI INTERNATIONAL INC.  
MANAGEMENT'S DISCUSSION AND ANALYSIS  
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017**

---

IV. Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due.

At September 30, 2017, the Company had current assets of \$351,560, including a cash balance of \$32,007, to settle current liabilities of \$591,323. The Company is currently subject to significant liquidity risks and remains dependant on the financial support of its debtors and shareholders. Refer to Note 1 in the financial statements for additional details.

V. Credit risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations.

The Company places its cash with institutions of high credit worthiness. Management has assessed there to be a low level of credit risk associated with its cash balances.

Receivables are due from customers. The credit risk with respect to these balances are influenced by the individual characteristics of each customer. The Company assesses the credit worthiness of each customer before standard payment and delivery terms are offered. Additionally, the Company monitors the aging accounts receivable and assesses risk of non-payment on an ongoing basis.

At September 30, 2017, the Company's goods and services tax receivable consists of amounts due from the Government of Canada. The Company believes the credit risk associated with this balance is minimal. Additionally, the Company has balances due from related parties. The Company anticipates that it will realize these balances through expenditures incurred on behalf of the Company by these related parties.

## **CHANGES IN ACCOUNTING POLICIES**

### **New standards and interpretations applicable in future periods**

Certain new standards, interpretations, amendments and improvements to existing standards were issued by the IASB or IFRIC that are mandatory for future accounting periods. The following have not yet been adopted by the Company and are being evaluated to determine their impact.

- IFRS 9: New standard that replaced IAS 39 for classification and measurement, effective for annual periods beginning on or after January 1, 2018.
- IFRS 15: Revenue from contracts with customers, which covers principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The effective date of the standard is annual reporting periods beginning on or after January 1, 2018, with earlier application permitted. The Company will not be early adopting IFRS 15. The Company is currently assessing the impact on the consolidated financial statements. An assessment has been completed on the sale of the Company's products. The Company does not

**NEUTRISCI INTERNATIONAL INC.  
MANAGEMENT'S DISCUSSION AND ANALYSIS  
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2017**

---

anticipate these sales to be significantly affected by IFRS 15 as the products are sold on a standalone basis. The Company will continue to assess the new revenue recognition policy and any related impact on internal controls throughout 2017.

- IFRS 16: A new standard that sets out the principles for recognition, measurement, presentation, and disclosure of leases including guidance for both parties to a contract, the lessee and the lessor. The new standard eliminates the classification of leases as either operating or finance leases as is required by IAS 17 and instead introduces a single lease accounting model.

### **OFF-BALANCE SHEET ARRANGEMENTS**

The Company currently has no off-balance sheet arrangements.

### **SUBSEQUENT EVENT**

Subsequent to September 30, 2017, the Company completed a non-brokered private placement, raising gross proceeds of \$324,550 by issuing 4,636,429 units at a price of \$0.07 per unit, with each unit consisting of one common share and one common share purchase warrant. The Company had received subscriptions of \$89,000 as at September 30, 2017. Each full warrant entitles the holder to acquire one additional common share at a price of \$0.12 per share until October 5, 2018.

In connection with the placement, the Company paid a cash commission totaling \$14,945 and issued 213,500 finder's warrants. Each finder's warrant entitles the holder to acquire one common share at a price of \$0.12 per share until October 5, 2018.

### **ADDITIONAL INFORMATION**

Additional information relating to the Company is available at [www.sedar.com](http://www.sedar.com).